Also trades as: ORMP.TA (TLV) · $vol 0M
ORMP NASDAQ
Oramed Pharmaceuticals Inc.
1W: +0.2%
1M: -12.4%
3M: +4.8%
YTD: +53.5%
1Y: +74.1%
3Y: +102.9%
5Y: -81.7%
$4.16
+0.08 (+1.96%)
Weekly Expected Move ±4.3%
$4
$4
$4
$4
$4
Credit Risk of going bust: lower than 87% of companies Debt: 0.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Oramed Pharmaceuticals Inc. would be worth roughly what it owes.
Total debt $733K against a stock market value of $173.0M.
Distance to default 12.25 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $249K (short-term plus half of long-term), stock volatility 52.7%; Altman Z'' 10.12. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Oramed Pharmaceuticals Inc. would be worth roughly what it owes.
Total debt $733K against a stock market value of $173.0M.
Distance to default 12.25 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $249K (short-term plus half of long-term), stock volatility 52.7%; Altman Z'' 10.12. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
50 relationships43
As Filer
counterparties named
7
As Counterparty
mentioned by others
7
Rel. Types
2021-03-19
Earliest Filing
2026-03-25
Latest Filing
partner: 24
investor: 5
target: 4
acquirer: 3
supplier: 3
JV: 3
customer: 1
Counterparties (Filed by ORMP)
43 relationshipsCompanies named in ORMP's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Scilex Holding Company | SCLXW | investor | Issued warrants to Oramed Pharmaceuticals Inc. in exchange for deferring an amortization payment on Senior Secured Conve | 2026-02-20 | View |
| Lifeward Ltd. | LFWD | acquirer | Acquired all outstanding equity interests in Oratech from Oramed Pharmaceuticals Inc. in exchange for shares, warrants, | 2026-01-14 | View |
| Oratech Pharma, Inc. | — | target | Wholly-owned subsidiary of Oramed Pharmaceuticals Inc. that was acquired by Lifeward Ltd. | 2026-01-14 | View |
| Hefei Tianhui Biotech Co., Ltd. | — | partner | Joint venture partner and counterparty to share repurchase agreement | 2025-10-24 | View |
| Scilex Holding Company | SCLXW | investor | Lender and warrant holder entering into an option agreement for warrant repurchase. | 2025-07-23 | View |
| Alpha Tau Medical Ltd. | DRTSW | acquirer | Oramed purchased 14.1M shares of Alpha Tau in a registered direct offering for $36.9M. | 2025-04-28 | View |
| Alpha Tau Medical Ltd. | DRTSW | customer | Alpha Tau engaged Oramed to provide strategic IR and PR services for a fee of $3M plus warrants. | 2025-04-28 | View |
| Scilex Holding Company | SCLXW | partner | Counterparty in convertible notes purchase agreement and royalty purchase agreement | 2025-03-03 | View |
| Scilex Pharmaceuticals Inc. | — | partner | Counterparty in royalty purchase agreement, license agreement, and security agreement | 2025-03-03 | View |
| RoyaltyVest Ltd | — | investor | Licensee and investor in Gloperba License Agreement and Royalty Purchase Agreement | 2025-03-03 | View |
| Scilex Holding Company | SCLXW | partner | Parent company providing guarantee for the license agreement. | 2025-02-27 | View |
| Scilex Pharmaceuticals Inc. | — | partner | Licensor granting rights to develop and commercialize lidocaine products. | 2025-02-27 | View |
| RoyaltyVest Ltd | — | partner | Licensee entity formed by investors to commercialize products outside the US. | 2025-02-27 | View |
| Oishi Koseido Co., Ltd. | — | supplier | Existing partner in the supply chain for lidocaine products. | 2025-02-27 | View |
| Itochu Chemical Frontier Corporation | ITOCF | supplier | Existing partner in the supply chain for lidocaine products. | 2025-02-27 | View |
| Oramed NewCo, Inc. | — | partner | Joint venture entity formed with HTIT for funding, development, and distribution of oral insulin products. | 2025-02-11 | View |
| Oramed Ltd. | ORMP | partner | Israeli subsidiary of Oramed Pharmaceuticals Inc. participating in the joint venture and asset transfer. | 2025-02-11 | View |
| Hefei Tianhui Biotech Co., Ltd. | — | partner | Chinese biotech partner entering a joint venture, supply agreement, and license agreement. | 2025-02-11 | View |
| Technowl Limited | — | partner | Entity referred to as HTIT Sub, participating in the joint venture and supply/license agreements. | 2025-02-11 | View |
| SCLX Stock Acquisition JV LLC | — | partner | Agreed to transfer Scilex common stock to Oramed Pharmaceuticals Inc. in consideration for the note extension. | 2025-01-22 | View |
| SCLX Stock Acquisition JV LLC | — | partner | Agreed to deliver shares to lenders in consideration for deferral of amortization payments. | 2025-01-03 | View |
| Oishi Koseido Co., Ltd. | — | partner | Signatory to Product Development and Commercial Supply Agreements regarding lidocaine products. | 2024-10-08 | View |
| Itochu Chemical Frontier Corporation | ITOCF | partner | Signatory to Product Development and Commercial Supply Agreements regarding lidocaine products. | 2024-10-08 | View |
| Scilex Pharmaceuticals Inc. | — | partner | Entered into royalty purchase and security agreements regarding lidocaine product rights. | 2024-10-08 | View |
| InClin, Inc. | — | supplier | Oramed Ltd. entered into a Master Services Agreement to retain InClin as a clinical research organization for a Phase 3 | 2024-09-26 | View |
| Rodman & Renshaw LLC | — | partner | Sales agent for at-the-market offering agreement | 2024-03-18 | View |
| Cantor Fitzgerald & Co. | — | partner | Counterparty to terminated controlled equity offering agreement | 2024-03-18 | View |
| Technowl Limited | — | JV | Wholly-owned indirect subsidiary of Hefei Tianhui Biotech Co., Ltd. and partner in the joint venture | 2024-01-23 | View |
| Hefei Tianhui Biotech Co., Ltd. | — | JV | Partner in a joint venture to develop oral insulin and POD technology | 2024-01-23 | View |
| Scilex Holding Company | SCLXW | target | Target company whose equity securities are being acquired by Oramed Pharmaceuticals Inc. | 2023-08-22 | View |
| Sorrento Therapeutics, Inc. | — | target | Seller of Scilex equity securities to Oramed Pharmaceuticals Inc. | 2023-08-22 | View |
| Sorrento Therapeutics, Inc. | — | acquirer | Seller of Scilex securities and debtor in bankruptcy proceedings | 2023-08-09 | View |
| Scilex Holding Company | SCLXW | target | Target company whose securities are being acquired by Oramed Pharmaceuticals | 2023-08-09 | View |
| Cantor Fitzgerald & Co. | — | partner | Agent for controlled equity offering agreement | 2021-09-01 | View |
| Canaccord Genuity LLC | — | partner | Counterparty to terminated equity distribution agreement | 2021-09-01 | View |
| Canaccord Genuity LLC | — | partner | Equity distribution agent for the Company's common stock offering. | 2021-07-15 | View |
| Canaccord Genuity LLC | — | partner | Equity distribution agent for the Company's common stock offering. | 2021-06-16 | View |
| Oramed Ltd. | ORMP | partner | Wholly-owned subsidiary of Oramed Pharmaceuticals Inc. | 2021-03-19 | View |
| Run Ridge LLC | — | investor | Investor in the joint venture | 2021-03-19 | View |
| Cutter Mill Capital LLC | — | investor | Investor in the joint venture | 2021-03-19 | View |
| Akers Biosciences Inc. | — | partner | Partner contributing cash and assets to the joint venture | 2021-03-19 | View |
| Premas Biotech Pvt. Ltd. | — | partner | Partner providing novel vaccine technology | 2021-03-19 | View |
| Oravax Medical Inc. | — | JV | Joint venture formed to develop oral COVID-19 vaccines | 2021-03-19 | View |
Mentioned As Counterparty
7 mentionsOther companies that named ORMP in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| LFWD Lifeward Ltd. | acquirer | Seller of shares in the Share Purchase Agreement. | 2026-03-25 | View |
| SCLXW Scilex Holding Co | investor | Received a warrant agreement in exchange for deferring an amortization payment on a Senior Secured Convertible Note. | 2026-02-20 | View |
| LFWD Lifeward Ltd. | acquirer | Delaware corporation being acquired in the Share Purchase Agreement | 2026-01-13 | View |
| SCLXW Scilex Holding Co | investor | Investor party to the October 2024 Securities Purchase Agreement and holder of Tranche B Notes. | 2025-10-01 | View |
| SCLXW Scilex Holding Co | investor | Holder of warrants repurchased via Option Agreement | 2025-07-23 | View |
| SCLXW Scilex Holding Co | partner | Partner in Royalty Purchase Agreement and Amendment No. 1 to ZTlido Royalty Purchase Agreement. | 2025-03-03 | View |
| SCLXW Scilex Holding Co | investor | Lender and investor in Senior Secured Promissory Note and warrants | 2024-09-23 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-17 | Shareholder Vote | View | |
| 2026-06-30 | Bylaws Amendment; Other Events; Exhibits | View | |
| 2026-03-31 | Material Agreement; Acquisition/Disposition | Agreement Acquisition | View |
| 2026-02-20 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2026-01-14 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2026-01-07 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-31 | Other Events | View | |
| 2025-12-31 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-17 | Entry into Material Definitive Agreement; Material Modification to Rights of Security Holders; Finan | Agreement | View |
| 2025-11-17 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-24 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Results of O | Agreement | View |
| 2025-10-06 | Other Events | View | |
| 2025-08-21 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-07-23 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-05-21 | Other Events | View | |
| 2025-04-28 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-03-03 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-02-27 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-02-11 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-01-22 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR